Moderna Soars on Plans to Seek Clearance for Covid Vaccine

FDA advisory panel to review data on Dec. 17, agency says - Vaccine was 94.1% effective in final analysis of 196 cases. Moderna Inc. requested clearance for its coronavirus vaccine in the U.S. after a new analysis showed the vaccine was highly effective in preventing Covid-19, with no serious safety problems. A Moderna spokesman said in a text message late afternoon Monday that its application for an emergency use authorization for its Covid shot had been delivered to the U.S. Food and Drug Administration. Earlier, the company had said in a statement it would seek clearance on Monday in both the U.S. and Europe.